- Home
- CSR vs OCS Comparison
CSR vs OCS Comparison
Compare CSR & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- OCS
- Stock Information
- Founded
- CSR 1970
- OCS 2003
- Country
- CSR United States
- OCS Switzerland
- Employees
- CSR N/A
- OCS N/A
- Industry
- CSR Real Estate Investment Trusts
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- CSR Real Estate
- OCS Health Care
- Exchange
- CSR Nasdaq
- OCS Nasdaq
- Market Cap
- CSR 965.4M
- OCS 869.8M
- IPO Year
- CSR N/A
- OCS N/A
- Fundamental
- Price
- CSR $58.68
- OCS $19.00
- Analyst Decision
- CSR Buy
- OCS Strong Buy
- Analyst Count
- CSR 7
- OCS 4
- Target Price
- CSR $68.57
- OCS $36.50
- AVG Volume (30 Days)
- CSR 116.0K
- OCS 31.4K
- Earning Date
- CSR 10-27-2025
- OCS 11-06-2025
- Dividend Yield
- CSR 5.22%
- OCS N/A
- EPS Growth
- CSR N/A
- OCS N/A
- EPS
- CSR N/A
- OCS N/A
- Revenue
- CSR $267,076,000.00
- OCS $960,668.00
- Revenue This Year
- CSR $5.34
- OCS $36.75
- Revenue Next Year
- CSR $2.80
- OCS $1,261.53
- P/E Ratio
- CSR N/A
- OCS N/A
- Revenue Growth
- CSR 3.44
- OCS N/A
- 52 Week Low
- CSR $52.76
- OCS $13.60
- 52 Week High
- CSR $75.92
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- CSR 51.01
- OCS 67.52
- Support Level
- CSR $57.62
- OCS $17.26
- Resistance Level
- CSR $59.81
- OCS $17.80
- Average True Range (ATR)
- CSR 1.35
- OCS 0.48
- MACD
- CSR -0.05
- OCS 0.17
- Stochastic Oscillator
- CSR 52.79
- OCS 82.99
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.